These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 2570521)

  • 21. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems.
    Saxena PR
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S80-8. PubMed ID: 1382170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The treatment of heart failure: the role of neurohumoral activation.
    Middlekauff HR; Mark AL
    Intern Med; 1998 Feb; 37(2):112-22. PubMed ID: 9550589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Galvao M
    Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease.
    Mancia G; Dell'Oro R; Quarti-Trevano F; Scopelliti F; Grassi G
    J Hypertens Suppl; 2006 Mar; 24(1):S51-6. PubMed ID: 16601574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations.
    Francis GS
    J Cardiovasc Pharmacol; 1998; 32 Suppl 1():S16-21. PubMed ID: 9731691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The management of heart failure and the scope for new therapies: what role for xamoterol?
    Campbell RW
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):59S-64S. PubMed ID: 2572256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic management of heart failure: neurohormonal agents.
    Moser DK
    Crit Care Nurs Clin North Am; 1993 Dec; 5(4):599-608. PubMed ID: 7905275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The neurohumoral axis in congestive heart failure.
    Francis GS; Goldsmith SR; Levine TB; Olivari MT; Cohn JN
    Ann Intern Med; 1984 Sep; 101(3):370-7. PubMed ID: 6147109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure.
    Grassi G; Cattaneo BM; Seravalle G; Lanfranchi A; Pozzi M; Morganti A; Carugo S; Mancia G
    Circulation; 1997 Aug; 96(4):1173-9. PubMed ID: 9286946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac adrenoceptors in the failing heart: effect of intervention.
    Fowler MB
    Eur Heart J; 1990 Apr; 11 Suppl A():13-8. PubMed ID: 1971585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neurohormonal compensation processes in chronic heart failure: the effect of drugs].
    van Zwieten PA; Lie KI
    Ned Tijdschr Geneeskd; 1994 Jun; 138(24):1208-13. PubMed ID: 7912411
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of vasopressin in congestive heart failure.
    Goldsmith SR
    Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S19-23. PubMed ID: 16970149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-adrenergic component of the sympathetic nervous system in congestive heart failure.
    Leier CV; Binkley PF; Cody RJ
    Circulation; 1990 Aug; 82(2 Suppl):I68-76. PubMed ID: 2164897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cardiac renin-angiotensin system in heart failure.
    Johnston CI; Fabris B; Yoshida K
    Am Heart J; 1993 Sep; 126(3 Pt 2):756-60. PubMed ID: 8362749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart.
    Gilbert EM; Sandoval A; Larrabee P; Renlund DG; O'Connell JB; Bristow MR
    Circulation; 1993 Aug; 88(2):472-80. PubMed ID: 8393389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure.
    Marlow HF
    Circulation; 1990 Feb; 81(2 Suppl):III93-8. PubMed ID: 1967561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure.
    Packer M
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):66-73. PubMed ID: 3037891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuro-endocrine changes as new targets in the drug treatment of congestive heart failure.
    van Zwieten PA
    Pharmacol Res Commun; 1988 Dec; 20(12):1017-23. PubMed ID: 2905474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibition, the sympathetic nervous system, and congestive heart failure. The Australian Zestril (Lisinopril) Study Group.
    Sloman G
    Am J Cardiol; 1992 Oct; 70(10):113C-118C. PubMed ID: 1329466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapeutic prospects of renin-angiotensin system inhibition.
    Corvol P
    Clin Exp Hypertens A; 1989; 11 Suppl 2():463-70. PubMed ID: 2691125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.